Promacta and Victoza drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Promacta (eltrombopag olamine) and Victoza (liraglutide). Common drug interactions include platelet count decreased among females and diabetes mellitus inadequate control among males.

The phase IV clinical study analyzes what interactions people have when they take Promacta and Victoza. It is created by eHealthMe based on reports of 15 people who take the same drugs from the FDA, and is updated regularly.

What is Promacta?

Promacta has active ingredients of eltrombopag olamine. It is often used in idiopathic thrombocytopenic purpura (itp). eHealthMe is studying from 17,758 Promacta users. Check the latest studies of Promacta.

What is Victoza?

Victoza has active ingredients of liraglutide. It is often used in diabetes. eHealthMe is studying from 42,880 Victoza users. Check the latest studies of Victoza.



On Jul, 12, 2026

15 people who take Promacta and Victoza together, and have interactions are studied.

Promacta and Victoza drug interactions.

What are the common drug interactions of Promacta and Victoza, by gender? *:

female:

  1. Platelet count decreased
  2. Alopecia (absence of hair from areas of the body)
  3. Arthralgia (joint pain)
  4. Decreased appetite
  5. Dyspepsia (indigestion)
  6. Headache (pain in head)
  7. Hepatitis a
  8. Hypertension (high blood pressure)
  9. Iron deficiency anaemia
  10. Nausea (feeling of having an urge to vomit)

male:

  1. Diabetes mellitus inadequate control
  2. Oedema peripheral (superficial swelling)
  3. Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures)
  4. Fatigue (feeling of tiredness)
  5. Furuncle (infection of the hair follicle)
  6. Gastric disorder (disease of stomach)
  7. Gastritis (inflammation of stomach)
  8. Hypertension (high blood pressure)
  9. Hypoventilation (too shallow or too slow breathing, which does not meet the needs of the body)
  10. Increased appetite

What are the common drug interactions of Promacta and Victoza, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Platelet count decreased
  2. Alopecia (absence of hair from areas of the body)
  3. Arthralgia (joint pain)
  4. Back pain
  5. Decreased appetite
  6. Dyspepsia (indigestion)
  7. Headache (pain in head)
  8. Hepatitis a
  9. Hypertension (high blood pressure)
  10. Iron deficiency anaemia

50-59:

  1. Calculus ureteric (stone in ureter)
  2. Mobility decreased (ability to move is reduced)
  3. Nephrolithiasis (calculi in the kidneys)
  4. Pneumonia
  5. Postrenal failure (postrenal acute renal failure)
  6. Pulmonary embolism (blockage of the main artery of the lung)
  7. Respiratory distress (difficulty in breathing)
  8. Respiratory failure (inadequate gas exchange by the respiratory system)
  9. Urinary tract disorder
  10. Diarrhoea

60+:

  1. Diabetes mellitus inadequate control
  2. Oedema peripheral (superficial swelling)
  3. Fatigue (feeling of tiredness)
  4. Furuncle (infection of the hair follicle)
  5. Gastric disorder (disease of stomach)
  6. Gastritis (inflammation of stomach)
  7. Hypertension (high blood pressure)
  8. Hypoventilation (too shallow or too slow breathing, which does not meet the needs of the body)
  9. Increased appetite
  10. Infection

What are the existing conditions these people have? *

  1. Idiopathic Thrombocytopenic Purpura (bleeding disorder in which the immune system destroys platelets, which are necessary for normal blood clotting): 4 people, 26.67%
  2. High Blood Pressure: 3 people, 20.00%
  3. Autoimmune Thrombocytopenia (isolated low platelet count (thrombocytopenia) with normal bone marrow and the absence of other causes of thrombocytopenia): 2 people, 13.33%
  4. Thrombocytopenia (decrease of platelets in blood): 1 person, 6.67%
  5. Hypersensitivity: 1 person, 6.67%
  6. High Blood Cholesterol: 1 person, 6.67%
  7. Depression: 1 person, 6.67%
  8. Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Promacta and Victoza?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Promacta and Victoza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Promacta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Victoza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Promacta and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Victoza and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on eltrombopag olamine and liraglutide (the active ingredients of Promacta and Victoza, respectively), and Promacta and Victoza (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: